ALPHA ADRENERGIC AGONISTS FOR CPR

用于 CPR 的 ALPHA 肾上腺素能激动剂

• 批准号: 2228623
• 负责人: William Paul Purcell
• 金额: $ 7.26万
• 依托单位: MOLECULAR DESIGN INTERNATIONAL, INC.
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-06-15 至 1994-12-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2228623
• 关键词: alpha adrenergic agent; artificial respiration; benzenesulfonamide; cardiopulmonary resuscitation; chemical synthesis; drug design /synthesis /production; ethanolamines; hormone analog; imidazole; norepinephrine

In the United States alone, approximately 450,000 people yearly suffer a cardiac arrest outside the hospital. Less than 10% of these patients are discharged from the hospital alive, and of these, approximately 60% suffer some form of permanent neurologic injury. The poor resuscitation rates and neurologic outcome result in part from the low level of myocardial and cerebral blood flow and oxygen delivery generated during cardiopulmonary resuscitation (CPR). While epinephrine (an alpha 1,2; beta-1,2 adrenergic agonist) is currently used during CPR to enhance perfusion, it is unclear what specific adrenergic agonist components are required to optimize hemodynamics and minimize toxicity (i.e. increases on oxygen consumption and ventricular dysrhythmias) in this setting. The specific aim of this study is to synthesize adrenergic agonists that will maximally enhance myocardial and cerebral hemodynamics, resuscitation rates (without the development of hemodynamically significant ventricular dysrhythmias), and neurologic outcome following resuscitation from cardiac arrest.

仅在美国，每年就有大约45万人患有 在医院外心脏骤停 其中不到10%的患者 活着出院，其中约60%的人患有 某种永久性神经损伤 低复苏率 和神经系统的结果部分是由于心肌和 心肺复苏过程中产生的脑血流量和氧输送 复苏（CPR）。 而肾上腺素（α 1，2; β-1，2肾上腺素能 激动剂）目前用于CPR期间以增强灌注，但尚不清楚 需要哪些特定的肾上腺素能激动剂成分来优化 血液动力学和最小化毒性（即增加耗氧量 和室性心律失常）。 本研究的具体目的是合成肾上腺素能激动剂， 最大限度地增强心脑血流动力学， 心率（无血流动力学显著心室 心律失常）和心脏复苏后的神经学结局 逮捕了